Methotrexaat Accord

Methotrexate, the active ingredient in Methotrexaat Accord, is an antimetabolite (folate antagonist) presented as an oral tablet for oral use. It is employed to manage autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as specific cancers including acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer, in adult patients.

GNH USA supplies Methotrexaat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and ensuring quality and regulatory compliance.

Methotrexaat Accord (methotrexate) is used across several disease families where folate metabolism is a therapeutic target. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes tumor growth as part of combination chemotherapy. - Breast cancer: used in adjuvant regimens to limit tumor recurrence. - Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

Methotrexaat Accord may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or weakness. - Mouth sores: inflammation of oral mucosa. - Elevated liver enzymes: mild hepatic irritation. - Low blood counts: mild leukopenia or anemia. - Hair thinning: temporary reduction in hair growth.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis. - Pulmonary fibrosis: progressive lung scarring. - Bone marrow failure: pancytopenia requiring medical intervention. - Renal impairment: acute kidney injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Methotrexaat Accord, clinicians should observe several safety measures to minimize risk. - Pregnancy contraindication: avoid use in pregnancy (Category X) due to teratogenic risk. - Renal function monitoring: assess creatinine clearance before and during therapy. - Hepatic monitoring: perform baseline and periodic liver function tests. - Hematologic surveillance: monitor complete blood count regularly. - Drug interactions: review concomitant medications for potential synergistic toxicity. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Methotrexaat Accord interacts with several agents that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors: may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: enhances hematologic toxicity.

Moderate Interactions (Monitor Closely): - Penicillins (e.g., ampicillin): can reduce renal clearance of methotrexate. - Sulfonamides: may increase risk of bone marrow suppression. - Live vaccines: immunosuppression may diminish vaccine efficacy.